2. Search Result
Search Result
Results for "

Carbonic anhydrase inhibition

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0122
    Topiramate
    4 Publications Verification

    McN 4853; RWJ 17021

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate
  • HY-B0242
    Sulfanilamide
    2 Publications Verification

    Sulphanilamide

    		 Bacterial Antibiotic Infection
    ulfanilamide (Sulphanilamide) is a potent and orally active sulfonamide antibiotic and can be a major intermediate of sulfamethoxazole biodegradation. Sulfanilamide also is a carbonic anhydrase inhibitor. Sulfanilamide shows inhibition on virus of lymphogranuloma venereum .
    Sulfanilamide
  • HY-161507
    hCAI/II-IN-8

    		Carbonic Anhydrase Cholinesterase (ChE) Metabolic Disease
    hCAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. hCAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC50 = 21.35 ± 0.39 nM (hCA I); 7.12 ± 0.12 nM (hCA II)). hCAI/II-IN-8 inhibits AChE and BChE as well(IC50 = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). . .
    hCAI/II-IN-8
  • HY-147955
    hCAI/II-IN-5

    		Carbonic Anhydrase Cholinesterase (ChE) Neurological Disease Metabolic Disease
    hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
    hCAI/II-IN-5
  • HY-147954
    α-Glycosidase-IN-1

    		Carbonic Anhydrase Cholinesterase (ChE) Neurological Disease Metabolic Disease
    α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonic anhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
    α-Glycosidase-IN-1
  • HY-163753
    Carbonic anhydrase inhibitor 25

    		Carbonic Anhydrase Others
    Carbonic anhydrase inhibitor 25 (compound 6a) is a potent carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 25 shows inhibition for hCA I and hCA II receptor .
    Carbonic anhydrase inhibitor 25
  • HY-173194
    Carbonic anhydrase inhibitor 29

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 29 (Compound 5d) is an inhibitor targeting carbonic anhydrase IX (CA IX) and XII (CA XII), with inhibition constants (Ki) of 26.6 nM for CA IX and 10.9 nM for CA XII. Carbonic anhydrase inhibitor 29 can be used in anticancer research .
    Carbonic anhydrase inhibitor 29
  • HY-147952
    AChE-IN-20

    		Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    AChE-IN-20 (compound M26) is a potent AChE inhibitor with IC50 value of 397.32 nM and with Ki value of 335.76 nM. AChE-IN-20 shows inhibition potency against hCA I , hCA II and α-GLY with IC50 values of 84.14, 69.24 and 52.08 nM and with Ki values of 97.86, 76.23 and 57.93 nM, respectively .
    AChE-IN-20
  • HY-129986
    hCAI/II-IN-9

    		Endogenous Metabolite Others
    hCAI/II-IN-9 is a carbonic anhydrase inhibitor with inhibitory activity against human carbonic anhydrase isoforms I, II, IX, and XII. The inhibition constants (Ki) of hCAI/II-IN-9 for hCA I are in the range of 7.9-894 nM, for hCA II are in the range of 7.5-1645 nM, for hCA IX are in the range of 5.0-240 nM, and for hCA XII are in the range of 0.47-2.83 nM. hCAI/II-IN-9 may have potential applications in inhibiting a variety of pathologies involving these carbonic anhydrase isoforms .
    hCAI/II-IN-9
  • HY-B0122A
    Topiramate lithium

    McN 4853 lithium; RWJ 17021 lithium

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate lithium
  • HY-110234
    Topiramate D12

    McN 4853 D12 ; RWJ 17021 D12

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate D12
  • HY-B0122S1
    Topiramate-13C

    McN 4853-13C; RWJ 17021-13C

    		 Isotope-Labeled Compounds iGluR Potassium Channel Sodium Channel GABA Receptor Calcium Channel Carbonic Anhydrase Neurological Disease
    Topiramate- 13C (McN 4853- 13C) is 13C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate-13C
  • HY-B0122R
    Topiramate (Standard)

    		iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate (Standard)
  • HY-B0242R
    Sulfanilamide (Standard)

    		Bacterial Antibiotic Infection
    Sulfanilamide (Standard) is the analytical standard of Sulfanilamide. This product is intended for research and analytical applications. ulfanilamide (Sulphanilamide) is a potent and orally active sulfonamide antibiotic and can be a major intermediate of sulfamethoxazole biodegradation. Sulfanilamide also is a carbonic anhydrase inhibitor. Sulfanilamide shows inhibition on virus of lymphogranuloma venereum .
    Sulfanilamide (Standard)
  • HY-W008343
    1,3-Dimethyluracil

    		Endogenous Metabolite Metabolic Disease
    1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively .
    1,3-Dimethyluracil
  • HY-B0122S
    Topiramate-13C6

    McN 4853-13C6; RWJ 17021-13C6

    		 Isotope-Labeled Compounds Potassium Channel iGluR Sodium Channel GABA Receptor Carbonic Anhydrase Calcium Channel Neurological Disease
    Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate-13C6
  • HY-110234R
    Topiramate D12 (Standard)

    		iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate D12 (Standard) is the analytical standard of Topiramate D12. This product is intended for research and analytical applications. Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate D12 (Standard)
  • HY-13650
    Indisulam
    Maximum Cited Publications
    12 Publications Verification

    E 7070

    		 Molecular Glues Carbonic Anhydrase Cancer
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .
    Indisulam

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: